A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated

Y. M. Chen, R. P. Perng, J. F. Shih, Y. C. Lee, C. S. Lee, C. M. Tsai, J. Whang-Peng

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Phase II studies have suggested that weekly paclitaxel has a higher response rate and better toxicity profile than the conventional schedule of once every 3 or 4 weeks. Our aim was to evaluate the efficacy of weekly paclitaxel plus cisplatin (PC) vs vinorelbine plus cisplatin (VC) in chemonaïve non-small-cell lung cancer (NSCLC) patients. From October 2000 to May 2002, 140 patients were enrolled. The treatment dose was P 66 mg m -2 intravenous infusion (i.v.) on days 1, 8, and 15, and C 60 mg m-2 i.v. on day 15, or V 23 mg m-2 i.v. on days 1, 8, and 15, and C 60 mg m-2 i.v. on day 15, every 4 weeks. In all, 281 cycles of PC and 307 cycles of VC were given to the patients in the PC and VC arms, respectively. There were 26 partial responses and one complete response (overall 38.6%) in the PC arm, and no complete responses, but 27 partial responses (overall 38.6%) in the VC arm. Myelosuppression was more common in the VC arm (P < 0.001). Peripheral neuropathy and myalgia were significantly more common in the PC arm (P < 0.001). The median time to disease progression was 6 months in the PC arm and 8.4 months in the VC arm (P = 0.0344). The median survival time was 11.7 months in the PC arm and 15.4 months in the VC arm (P = 0.297). We concluded that weekly PC is not suggested for NSCLC patients due to the relatively shorter progression-free survival and more common nonhaematological toxicities.

Original languageEnglish
Pages (from-to)359-365
Number of pages7
JournalBritish Journal of Cancer
Volume90
Issue number2
DOIs
Publication statusPublished - Jan 26 2004
Externally publishedYes

Fingerprint

Paclitaxel
Non-Small Cell Lung Carcinoma
Cisplatin
Intravenous Infusions
vinorelbine
Myalgia
Peripheral Nervous System Diseases
Disease-Free Survival
Disease Progression
Appointments and Schedules

Keywords

  • Cisplatin
  • Non-small-cell lung cancer
  • Paclitaxel
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated. / Chen, Y. M.; Perng, R. P.; Shih, J. F.; Lee, Y. C.; Lee, C. S.; Tsai, C. M.; Whang-Peng, J.

In: British Journal of Cancer, Vol. 90, No. 2, 26.01.2004, p. 359-365.

Research output: Contribution to journalArticle

@article{242ac5ee8dce4d77b3d5831557b26121,
title = "A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated",
abstract = "Phase II studies have suggested that weekly paclitaxel has a higher response rate and better toxicity profile than the conventional schedule of once every 3 or 4 weeks. Our aim was to evaluate the efficacy of weekly paclitaxel plus cisplatin (PC) vs vinorelbine plus cisplatin (VC) in chemona{\"i}ve non-small-cell lung cancer (NSCLC) patients. From October 2000 to May 2002, 140 patients were enrolled. The treatment dose was P 66 mg m -2 intravenous infusion (i.v.) on days 1, 8, and 15, and C 60 mg m-2 i.v. on day 15, or V 23 mg m-2 i.v. on days 1, 8, and 15, and C 60 mg m-2 i.v. on day 15, every 4 weeks. In all, 281 cycles of PC and 307 cycles of VC were given to the patients in the PC and VC arms, respectively. There were 26 partial responses and one complete response (overall 38.6{\%}) in the PC arm, and no complete responses, but 27 partial responses (overall 38.6{\%}) in the VC arm. Myelosuppression was more common in the VC arm (P < 0.001). Peripheral neuropathy and myalgia were significantly more common in the PC arm (P < 0.001). The median time to disease progression was 6 months in the PC arm and 8.4 months in the VC arm (P = 0.0344). The median survival time was 11.7 months in the PC arm and 15.4 months in the VC arm (P = 0.297). We concluded that weekly PC is not suggested for NSCLC patients due to the relatively shorter progression-free survival and more common nonhaematological toxicities.",
keywords = "Cisplatin, Non-small-cell lung cancer, Paclitaxel, Vinorelbine",
author = "Chen, {Y. M.} and Perng, {R. P.} and Shih, {J. F.} and Lee, {Y. C.} and Lee, {C. S.} and Tsai, {C. M.} and J. Whang-Peng",
year = "2004",
month = "1",
day = "26",
doi = "10.1038/sj.bjc.6601526",
language = "English",
volume = "90",
pages = "359--365",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated

AU - Chen, Y. M.

AU - Perng, R. P.

AU - Shih, J. F.

AU - Lee, Y. C.

AU - Lee, C. S.

AU - Tsai, C. M.

AU - Whang-Peng, J.

PY - 2004/1/26

Y1 - 2004/1/26

N2 - Phase II studies have suggested that weekly paclitaxel has a higher response rate and better toxicity profile than the conventional schedule of once every 3 or 4 weeks. Our aim was to evaluate the efficacy of weekly paclitaxel plus cisplatin (PC) vs vinorelbine plus cisplatin (VC) in chemonaïve non-small-cell lung cancer (NSCLC) patients. From October 2000 to May 2002, 140 patients were enrolled. The treatment dose was P 66 mg m -2 intravenous infusion (i.v.) on days 1, 8, and 15, and C 60 mg m-2 i.v. on day 15, or V 23 mg m-2 i.v. on days 1, 8, and 15, and C 60 mg m-2 i.v. on day 15, every 4 weeks. In all, 281 cycles of PC and 307 cycles of VC were given to the patients in the PC and VC arms, respectively. There were 26 partial responses and one complete response (overall 38.6%) in the PC arm, and no complete responses, but 27 partial responses (overall 38.6%) in the VC arm. Myelosuppression was more common in the VC arm (P < 0.001). Peripheral neuropathy and myalgia were significantly more common in the PC arm (P < 0.001). The median time to disease progression was 6 months in the PC arm and 8.4 months in the VC arm (P = 0.0344). The median survival time was 11.7 months in the PC arm and 15.4 months in the VC arm (P = 0.297). We concluded that weekly PC is not suggested for NSCLC patients due to the relatively shorter progression-free survival and more common nonhaematological toxicities.

AB - Phase II studies have suggested that weekly paclitaxel has a higher response rate and better toxicity profile than the conventional schedule of once every 3 or 4 weeks. Our aim was to evaluate the efficacy of weekly paclitaxel plus cisplatin (PC) vs vinorelbine plus cisplatin (VC) in chemonaïve non-small-cell lung cancer (NSCLC) patients. From October 2000 to May 2002, 140 patients were enrolled. The treatment dose was P 66 mg m -2 intravenous infusion (i.v.) on days 1, 8, and 15, and C 60 mg m-2 i.v. on day 15, or V 23 mg m-2 i.v. on days 1, 8, and 15, and C 60 mg m-2 i.v. on day 15, every 4 weeks. In all, 281 cycles of PC and 307 cycles of VC were given to the patients in the PC and VC arms, respectively. There were 26 partial responses and one complete response (overall 38.6%) in the PC arm, and no complete responses, but 27 partial responses (overall 38.6%) in the VC arm. Myelosuppression was more common in the VC arm (P < 0.001). Peripheral neuropathy and myalgia were significantly more common in the PC arm (P < 0.001). The median time to disease progression was 6 months in the PC arm and 8.4 months in the VC arm (P = 0.0344). The median survival time was 11.7 months in the PC arm and 15.4 months in the VC arm (P = 0.297). We concluded that weekly PC is not suggested for NSCLC patients due to the relatively shorter progression-free survival and more common nonhaematological toxicities.

KW - Cisplatin

KW - Non-small-cell lung cancer

KW - Paclitaxel

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=1342301553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342301553&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601526

DO - 10.1038/sj.bjc.6601526

M3 - Article

C2 - 14735177

AN - SCOPUS:1342301553

VL - 90

SP - 359

EP - 365

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -